MARK KESSEL
CIK 1222013 · last filed 2019-09-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
16
Lifetime Open-Market Net
-$28.36M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VivoSim Labs, INC. (ONVO) Delisted | Director | 62 | $2.04 | $126 | $0 | 4 | 2019-09-09 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 303,143 | $15.50 | $4.70M | -$28.36M | 7 | 2012-10-17 |
| Oncotelic Therapeutics, Inc. (OXGN) Delisted | Director | 1,361,606 | — | — | $0 | 5 | 2011-01-04 |
Recent Filings · Page 2 of 2
16 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-05-14 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-04-20 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Other (J) | +690,631 | $0 | EDGAR |
| 2010-01-05 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Grant (A) | +35,000 | $39.9K | EDGAR |
| 2010-01-04 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-10 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Grant (A) | +30,000 | $34.2K | EDGAR |
| 2009-07-22 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Other (J) | +10,000,000 | $12.48M | EDGAR |
Showing 11–16 of 16
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.